Company profile
ExplantLab | Orthotype Next Generation Orthopaedics
An Orthogenomic Biotech providing healthcare professionals with patient focused tools to help eliminate the failure of orthopaedic implants.
Financial period: 1 Feb 2024 to 31 Jan 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
PSC07 | Transaction MzUxNTM5MzIwN2FkaXF6a2N4
Published 10 Apr 2026 14:32
PSC01 | Transaction MzUxNTM5MzEzOGFkaXF6a2N4
Published 10 Apr 2026 14:32
Last confirmation statement made up date
Last accounts made up date
RP04CS01 | Transaction MzQ0NDc0NTg4OGFkaXF6a2N4
Published 25 Nov 2024 04:11
AA | Transaction MzQ0MTYxNjM4M2FkaXF6a2N4
Published 31 Oct 2024 02:01
CS01 | Transaction MzQxMjU1MDQwM2FkaXF6a2N4 | Paper/PDF filed
Published 27 Nov 2024 10:55
Company registered at Companies House
1 Aug 2023 to 31 Jul 2025
PXD Ltd have developed the world's first and only algorithm (Orthotype) to determine pre-operatively the risk of a patient developing sensitivity to Cobalt-Chromium (CoCr) knee or joint replacements. Triangulating specific genetic biomarkers with other data, Orthotype helps prevent future failure of implants in patients due to allergic responses governed ...
1 Jun 2020 to 28 Feb 2021
Major histocompatibility complex (MHC) genes underpin host response to pathogens, including Covid-19\. MHC proteins have a functional peptide binding groove (PBG) that binds foreign peptides (antigens) within a cell. Once bound, the MHC-antigen complex translocates to the surface of the cell, which then stimulate an immune response. MHC genes thus play a ...
1 Dec 2019 to 31 May 2021
Over 160,000 NHS patients undergo knee and hip arthroplasty surgery each year. A number of these surgeries will fail, requiring costly and complex revision surgery, which carries an increased risk for the patient. An increasing body of scientific evidence suggests metal allergies are responsible for many of these failures. Wear and tear metal-containing i...
